| Association between EPHA5 methylation status in peripheral blood leukocytes and the risk and prognosis of gastric cancer. | Association between EPHA5 methylation status in peripheral blood leukocytes and the risk and prognosis of gastric cancer.
Han X, Liu T, Zhai J, Liu C, Wang W, Nie C, Wang Q, Zhu X, Zhou H, Tian W., Free PMC Article | 02/14/2023 |
| Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients. | Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients.
Abouhashem N, Harb O, Elwan A, Zaitoun M, Saraya Y. | 11/12/2022 |
| Expression of EPHA5 in lung adenocarcinoma is associated with lymph node metastasis and EGFR mutation. | Expression of EPHA5 in lung adenocarcinoma is associated with lymph node metastasis and EGFR mutation.
Liu C, He Y, Feng X, Li J, Wang J. | 05/28/2022 |
| Deep learning model reveals potential risk genes for ADHD, especially Ephrin receptor gene EPHA5. | Deep learning model reveals potential risk genes for ADHD, especially Ephrin receptor gene EPHA5.
Liu L, Feng X, Li H, Cheng Li S, Qian Q, Wang Y., Free PMC Article | 03/12/2022 |
| Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. | Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
Marcath LA, Kidwell KM, Vangipuram K, Gersch CL, Rae JM, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Smith EML, Henry NL, Beutler AS, Hertz DL., Free PMC Article | 08/21/2021 |
| EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion. | EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion.
Zhang J, Zhang Z, Song W, Liu J. | 06/5/2021 |
| EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. | EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Chen Z, Chen J, Ren D, Zhang J, Yang Y, Zhang H, Mao B, Ma H., Free PMC Article | 05/8/2021 |
| Gene-based analysis identified EPHA6 as the gene most significantly associated with paclitaxel-induced neuropathy...This first study sequencing EPHA genes revealed that low-frequency variants in EPHA6, EPHA5, and EPHA8 contribute to the susceptibility to paclitaxel-induced neuropathy | Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
Apellániz-Ruiz M, Tejero H, Inglada-Pérez L, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, Castelo B, Redondo A, García-Donás J, Romero-Laorden N, Sereno M, Merino M, Currás-Freixes M, Montero-Conde C, Mancikova V, Åvall-Lundqvist E, Green H, Al-Shahrour F, Cascón A, Robledo M, Rodríguez-Antona C. | 02/10/2018 |
| Our data indicate that EphA5 receptor may be a tumor suppressor in colorectal carcinoma and it may be a new therapeutic target for colorectal carcinoma. | Reduced expression of EphA5 is associated with lymph node metastasis, advanced TNM stage, and poor prognosis in colorectal carcinoma.
Gu S, Feng J, Jin Q, Wang W, Zhang S. | 08/19/2017 |
| EphA5 protein was negatively (0) or weakly (1+) expressed in 48 of 78 (61.5%), moderately (2+) expressed in 15 of 78 (19.2%) and strongly (3+) expressed in 15 of 78 (19.2%) tumour samples of clear cell renal cell carcinoma (ccRCC). Decreased expression of EphA5 was detected more often in females than in males | Decreased expression of EphA5 is associated with Fuhrman nuclear grade and pathological tumour stage in ccRCC.
Wang X, Xu H, Wu Z, Chen X, Wang J., Free PMC Article | 08/12/2017 |
| the interactions of EphA5/ephrinA5 and/or EphA7/ephrinA5 between HSPCs and BMSCs, independently and cooperatively, play a role in HSPC colony formation through the upregulation of GM-CSFR. Furthermore, the adhesion/migration of HSPCs appears to be mediated in part through the activation of Rac1. | EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance, migration, and adhesion via Rac1 activation.
Nguyen TM, Arthur A, Zannettino AC, Gronthos S. | 06/10/2017 |
| Our results show that EphA5 may be a potential biomarker for distinguishing high-and low-grade ovarian serous carcinoma and a potential prognostic marker. | EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X, Wang X, Wei X, Wang J., Free PMC Article | 04/8/2017 |
| Our study provides evidence that EphA5 is a potential target for epigenetic silencing in primary prostate cancer and is a potentially valuable prognosis predictor and thereapeutic marker for prostate cancer. | Downregulation of EphA5 by promoter methylation in human prostate cancer.
Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, Wu Z, Wang H, Xu X, Zhang H, Ren G, Tang J, Li X, Guan M., Free PMC Article | 01/16/2016 |
| demonstrate that a new monoclonal antibody against human EphA5 sensitized lung cancer cells and human lung cancer xenografts to radiotherapy and significantly prolonged survival, thus suggesting the likelihood of translational applications | Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer.
Staquicini FI, Qian MD, Salameh A, Dobroff AS, Edwards JK, Cimino DF, Moeller BJ, Kelly P, Nunez MI, Tang X, Liu DD, Lee JJ, Hong WK, Ferrara F, Bradbury AR, Lobb RR, Edelman MJ, Sidman RL, Wistuba II, Arap W, Pasqualini R., Free PMC Article | 07/4/2015 |
| unbound EphA5 LBD appears to comprise an ensemble of open conformations that have only small variations over the loops and appear ready to bind ephrin-A ligands | Unique structure and dynamics of the EphA5 ligand binding domain mediate its binding specificity as revealed by X-ray crystallography, NMR and MD simulations.
Huan X, Shi J, Lim L, Mitra S, Zhu W, Qin H, Pasquale EB, Song J., Free PMC Article | 07/19/2014 |
| These results indicate that EphA5 may be a negative regulator of bone formation. | After repeated division, bone marrow stromal cells express inhibitory factors with osteogenic capabilities, and EphA5 is a primary candidate.
Yamada T, Yuasa M, Masaoka T, Taniyama T, Maehara H, Torigoe I, Yoshii T, Shinomiya K, Okawa A, Sotome S. | 06/14/2014 |
| Insertional translocation leading to a 4q13 duplication including the EPHA5 gene is associated with attention-deficit. hyperactivity disorder | Insertional translocation leading to a 4q13 duplication including the EPHA5 gene in two siblings with attention-deficit hyperactivity disorder.
Matoso E, Melo JB, Ferreira SI, Jardim A, Castelo TM, Weise A, Carreira IM. | 10/19/2013 |
| these data suggest that miR-34a is a negative modulator of chondrogenesis, particularly in migration of chondroblasts, by targeting EphA5 and resulting inhibition of cellular condensation during chondrogenesis of chick limb mesenchymal cells. | MicroRNA-34a regulates migration of chondroblast and IL-1β-induced degeneration of chondrocytes by targeting EphA5.
Kim D, Song J, Kim S, Chun CH, Jin EJ. | 01/28/2012 |
| Eph-A5 and Eph-A7 staining intensity was identified as independent prognostic factors for pancreatic ductal adenocarcinoma | Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.
Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, Kouraklis G, Chatzopoulou E, Dimakopoulou K, Theocharis SE. | 08/23/2010 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| EphA5 might be a potential target for epigenetic silencing in primary breast cancer and a valuable molecular marker for breast cancer carcinogenesis and progression. | Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
Fu DY, Wang ZM, Wang BL, Chen L, Yang WT, Shen ZZ, Huang W, Shao ZM. | 01/21/2010 |
| increased levels of ephrins A1 and A5 in the presence of high expression of Ephs A1 and A2 lead to a more aggressive ovarian cancer phenotype | Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival.
Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, Lincoln D, Boyle G, Parsons PG, Boyd AW., Free PMC Article | 01/21/2010 |